The addition of lenvatinib and pembrolizumab to chemotherapy did not extend OS for certain patients with advanced ...

The company announced interim data showing strong systemic responses in its safety and efficacy study combining Alpha DaRT treatment with ...

About 61% of patients with stage I or II dMMR colon cancer achieved a pathologic complete response after a single cycle of neoadjuvant pembrolizumab, new data revealed.

The LEAP-015 study is evaluating Merck's Keytruda and Eisai's Lenvima plus chemotherapy in certain types of gastroesophageal ...

Results have been announced from a Phase III trial of Merck & Co’s anti-PD-1 therapy Keytruda (pembrolizumab) plus Lenvima ...

Cancer patients to receive relief on imported medicines through Basic Customs Duty exemptions and patient assistance programmes.

Merck Sharp & Dohme, Millennium Pharmaceutical, Bristol-Myers Squibb, Incyte Corporation, Immune Oncology Network, Sotio Biotech Inc, Regeneron Pharmaceuticals, and others .Key Merkel Cell ...

High disease control rate and strong interim safety results observed in pancreatic cancer patients across three trials exploring the use of ...

Budget 2025: Seeks to further amend notification No. 16/2017-Customs, dated the 20th April, 2017 so to exempt certain drugs for supply under Patient Assistance Programme run by specified ...

observed for pembrolizumab alone in a similar patient population in Merck’s KEYNOTE-048 trial - - Alpha Tau is hosting a virtual R&D Update Day with Key Opinion Leaders at 11:00am ET today ...

SELLAS Life Sciences Group, Inc.’s SLS share price has surged by 21.80%, which has investors questioning if this is right time to sell.

New Delhi: Finance Minister Nirmala Sitharaman announced a full exemption from basic customs duty (BCD) for 36 live-saving drugs to treat cancer, rare diseases, and other chronic conditions in her ...